Background {#Sec1}
==========

There is substantial evidence for a role of female hormones in the etiology of breast cancer. Reproductive factors, such as early age at menarche, nulliparity, and late age at first birth \[[@CR1]--[@CR3]\] are all believed to be associated with breast cancer risk through hormonal mechanisms. Current use of oral contraceptives is associated with some increased risk of breast cancer \[[@CR4]--[@CR6]\]. Likewise, combined postmenopausal hormone therapy (estrogen and progesterone), increases the risk of breast cancer \[[@CR7]--[@CR16]\]. However, breast cancer consists of several molecular subtypes that have very different prognoses \[[@CR17]--[@CR23]\]. It is less clear whether these various subtypes have different etiologies. There have been two main challenges in previous literature: the various definitions used to define breast cancer subtypes, and the lack of power to examine the effect on all subtypes.

In earlier studies, subtypes were defined by immunohistochemical analysis (IHC) of the two hormone receptors only, i.e. the estrogen receptor (ER) and the progesterone receptor (PR) \[[@CR24]--[@CR31]\]. It is only in recent years that studies have been conducted incorporating data on human epidermal growth factor receptor 2 (HER2) status \[[@CR32]--[@CR38]\], with a few having included other additional molecular markers \[[@CR3], [@CR34], [@CR39]--[@CR44]\]. However, most studies so far have not been able to run molecular expression studies on a large scale. This may not be necessary however, because there is a large degree of overlap between the immunohistochemical subtypes defined by ER, PR, and HER2 status and those identified by molecular expression studies \[[@CR18]--[@CR21], [@CR45]\]. However, a challenge has been that investigators have used various definitions and specific markers to define breast cancer subtypes, such as luminal B tumors. Further, using the molecular terms luminal A, B, or basal gives the impression that they are defined using molecular expression markers, whereas they are based on IHC. Investigators at the St. Gallen meeting in 2013 therefore suggested that the term "like" should be added to the molecularly derived "luminal" subtype names (e.g. "luminal A-like", "luminal B-like") to indicate that IHC was used to define these subtypes \[[@CR46]\] and hence, that they are proxies of the molecular subtypes.

Another challenge has been that many studies have not had adequate power to assess the effect of risk factors on all subtypes, which makes it difficult to determine the effect of risk factors on the less common subtypes. The overall published evidence \[[@CR7], [@CR8], [@CR10], [@CR47]--[@CR50]\] seems to be consistent with luminal A-like cancers having a hormonal etiology, but the association between hormonal factors and other subtypes, in particular luminal B-like disease, HER2-positive disease, and triple-negative cancer, is less clear. Specifically, reproductive factors such as parity and early age at first birth have been associated with reduced risk of luminal A-like disease. There is less evidence of a protective effect of parity on luminal B-like and HER2-positive cancers and parity has consistently been found not to protect against triple-negative disease \[[@CR7], [@CR47]--[@CR50]\]. There is some, albeit inconsistent, evidence that older age at menarche and breastfeeding may protect against all subtypes \[[@CR7], [@CR8], [@CR47], [@CR49]--[@CR52]\] suggesting that these protective effects may work through non-hormonal mechanisms. The use of menopausal hormone therapy has been consistently associated with an increased risk of luminal A-like breast cancer, but the evidence is less clear for risk of luminal B-like, HER2-positive and triple-negative breast cancer \[[@CR10], [@CR47], [@CR49]\].

We decided to take advantage of a national screening program in Norway to examine potential associations between reproductive and hormonal factors and the various breast cancer subtypes - specifically, luminal A-like, luminal B-like HER2-negative, luminal B-like HER2-positive, HER2-positive, and triple-negative disease - in a large study. We therefore conducted a large nested case-control study within the Norwegian Breast Cancer Screening Program.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The Cancer Registry of Norway (CRN) is responsible for the administration of the Norwegian Breast Cancer Screening Program \[[@CR53]\]. Women aged 50--69 years are invited to undergo two-view mammography screening every 2 years. From August 2006, women, who underwent mammographic screening in the national program were asked to complete a questionnaire on a number of standard breast cancer risk factors, and another questionnaire on current exposure variables at subsequent screenings. For the current study cohort, women who had participated in the Norwegian Breast Cancer Screening Program during 2006 to 2014 and had completed these questionnaires were eligible for inclusion. The study cohort comprised a total of 344,348 eligible women. Information on cancer cases was obtained through linkage to the population-based CRN records using the unique 11-digit personal identification number assigned to all residents at time of birth. This linkage also included information on vital status, including date and cause of death/date of emigration if applicable. Reporting of cancer to the CRN is mandatory by law, and the registry is considered to be 98.8% complete \[[@CR54]\].

All women aged 50--69 years who are included in the National Population Registry are invited to undergo screening as part of the Norwegian Breast Cancer Screening Program every 2 years. The average attendance rate in each round is about 76%.

We conducted a nested case-control study within the study cohort. Only women with no history of ductal carcinoma in situ prior to the study start (1 January 2006) and no history of diagnosis of another invasive cancer (except non-melanoma skin cancer) were eligible for the study. The cases were women diagnosed with a first occurrence of invasive breast cancer (ICD10: C50) during the study period, with information on ER, PR, and HER2 status (see subsequent text). For each woman with breast cancer, we randomly selected five controls individually matched to cases by year of birth (+/- 3 years) and year of last screening before breast cancer diagnosis (+/- 3 years). Controls had to be alive and resident in the country at the time of the diagnosis of breast cancer in the matching case. We ended up with 6471 patients with breast cancer (cases) and 32,355 controls. The study was approved by the Regional Committee for Medical and Health Research Ethics in the South-East Health Region of Norway.

Tumor receptor status ascertainment {#Sec4}
-----------------------------------

Information on ER, PR and HER2 status was assessed by IHC and extracted from pathology reports submitted to the CRN. From 2006 to January 2012, tumors were classified as ER-negative if there was \<10% reactivity. From February 2012 onwards, the threshold for ER-negative tumors was changed to \<1% reactivity as a result of change in the treatment protocols for patients attending clinics in Norway. We used these official thresholds. PR-negative tumors were defined as those with reactivity of \<10%, and PR-positive tumors as those with reactivity ≥10%. HER2 expression status was determined at each laboratory with IHC and/or in situ hybridization. Cases with no (0) or weak (1+) immunostaining were defined as HER2-negative, while cases with moderate (2+) or strong immunostaining (3+) were defined as HER2-positive. In situ hybridization (fluorescence (FISH), chromogenic (CISH), or silver (SISH) in situ hybridization methods) was usually used to confirm HER2 status if IHC yielded 2+ results. If IHC was 2+ and FISH, CISH, or SISH were missing, or if IHC was missing but FISH, CISH, or SISH were positive, the tumor was classified as HER2-positive. If IHC was 2+ and FISH, CISH, and SISH were negative, the tumor was regarded as HER2-negative. Data on Ki-67 were recorded by the CRN from late 2011 and therefore, we did not include this marker in our analysis.

Risk factors {#Sec5}
------------

Our primary exposures of interest were hormonal risk factors including reproductive factors (age at first birth, number of pregnancies, breastfeeding, menopausal status), and other hormonal factors (use of oral contraceptives, intrauterine devices (IUD) and menopausal hormone therapy use). Menopausal hormone therapy use included use of estrogen alone (estrogen therapy, ET), or use of combined estrogen and progestin therapy (EPT). For current exposures we chose the questionnaire at the last screening before breast cancer diagnosis for the cases and the corresponding time for the controls. If the questionnaire or any values were missing, information was used from the previous screening questionnaire. Menopausal status was defined according to whether or not women were still menstruating, or whether they menstruated irregularly. Menopausal age was defined as the age when menstruation ended.

Confounders and missing values {#Sec6}
------------------------------

We considered age at screening (50--54, 55--59, 60--64, or 65--70 years), body mass index (BMI) at screening (≤22, 23--25, 26-28, or \>28), education (no education/primary school, high school, or bachelor's/master's degree), age at menarche (9--12, 13, 14, or 15--18 years), number of pregnancies lasting at least six months (never pregnant, 1, 2, 3, or ≥4) and menopausal status (premenopausal, perimenopausal, or postmenopausal) as potential confounders and adjusted for these when appropriate. We tried to control more tightly for age at screening using a continuous variable, but the results remained largely the same, and we therefore retained the 5-year categories.

Women with missing values for an exposure variable were excluded from the analyses of that variable, while women with missing information on the potential confounding variables listed previously were excluded from all analyses. Of the 6471 patients with breast cancer, we excluded women due to missing information on the following variables: BMI (*n* = 532 patients), age at menarche (*n* = 298 patients), education (*n* = 66 patients), number of pregnancies (*n* = 164 patients), and menopausal status (*n* = 59 patients). This left us with 5352 women with breast cancer (cases) for analysis. Of the 32,355 controls, we excluded controls based on missing information on the following: BMI (*n* = 3296 controls), age at menarche (*n* = 1641 controls), education (*n* = 371 controls), number of pregnancies (*n* = 779 controls), and menopausal status (*n* = 336 controls). This left us with 25,932 controls for analysis.

The cases were categorized by breast cancer subtype using a modified version of the classification of clinically defined subtypes proposed at the St. Gallen meeting in 2013 \[[@CR46]\]. Of the 5352 cases of breast cancer, 604 had unknown hormone receptor (i.e. ER and/or PR) and HER2 status or could not be classified into the breast cancer subtypes. There were 4748 women with breast cancer classified into the following subtypes: 2985 women with luminal A-like breast cancer (ER+ PR+ HER2-), 758 women with luminal B-like HER2-negative breast cancer (ER+ PR- HER2-), 396 women with luminal B-like HER2-positive breast cancer (ER+ PR+/PR- HER2+), 223 women with HER2-positive breast cancer (ER- PR- HER2+) and 386 women with triple-negative breast cancer (ER- PR- HER2-). As we did not have Ki-67 results, we conducted sensitivity analysis where we added grade to the luminal subtype definitions in an attempt to better separate out these subtypes, using the definitions from the St. Gallen 2013 meeting \[[@CR46]\]. In this analysis luminal A-like subtype was defined as ER+ PR+ HER2-, low or medium grade, luminal B-like HER2-negative as ER+ PR- HER2-, high grade, and luminal B-like HER2-positive as ER+ PR-/PR+ HER2+, any grade.

Statistical analyses {#Sec7}
--------------------

We used conditional logistic regression to estimate odds ratios (with 95% confidence intervals (CI)) as a measure of relative risk associated with various exposures. Trend tests were performed by fitting ordinal values corresponding to exposure categories and testing whether the slope coefficient differed from zero. To test for heterogeneity between breast cancer subtypes we ran case--case analyses, comparing each subtype to the luminal-A-like subtype. We used likelihood ratio tests comparing the likelihood ratio of the case--case model with confounders only to that of the adjusted case--case model with the exposure variable. We considered a two-sided *p* value \<0.05 as statistically significant.

Because we used conditional logistic regression we included all women in the risk estimates (e.g. women who were never pregnant were included in analysis of age at first birth, women who never used oral contraceptives (OC) were included in analysis of age at the start of OC, and premenopausal women were included in analysis of age at menopause), but they were not included in the trend test (dummy variables were added into the analysis).

Results {#Sec8}
=======

BMI, age at first birth, education, age at menopause, duration of use of oral contraceptives and intrauterine devices, and menopausal hormone therapy use were positively associated with overall breast cancer risk (i.e. all subtypes combined) whereas age at menarche, number of pregnancies and postmenopausal status were associated with a decreased risk (Table [1](#Tab1){ref-type="table"}).Table 1Adjusted odds ratios (ORs) and 95% confidence intervals (CI) for association between breast cancer overall and education and reproductive and hormonal risk factorsCharacteristicsOverallTotal (*n*)Controls (*n*)Cases (n)OR\*95% CIEducation No education/primary school8584719213921Ref High school12,78110,58221991.07(0.99, 1.15) University Bachelor's degree6179508110981.11(1.01, 1.22) University Master's degree374030776631.10(0.98, 1.22)  *p*-trend\*0.03BMI (kg/m^2^)  \< = 22514143338081Reference 23--259655807515801.07(0.98, 1.18) 26--288131669414371.19(1.08, 1.32) \>288357683015271.23(1.12, 1.36)  *p*-trend\<0.0001Age at menarche (years) 9--129296761516811Reference 138628715714710.93(0.86, 1.01) 147704643912650.89(0.82, 0.97) 15--18565647219350.90(0.82, 0.98)  *p*-trend0.01Age at first birth (years) 13--208413708513281Reference 21--22499441708241.04(0.94, 1.15) 23--256673558010931.02(0.93, 1.12) 26--30544044979431.09(0.98, 1.20) 31--50207016414291.29(1.12, 1.48) Never given birth (nulliparous)273021445861.73(1.49, 2.01)  *p*-trend^a^0.003Number of pregnancies lasting 6+ months 0273021445861Reference 1358429116730.83(0.73, 0.94) 2134991100023010.76(0.68, 0.84) 38307695613510.71(0.63, 0.79) \>4316427234410.59(0.51, 0.68)  *p*-trend\<0.0001Parous women only Duration of breastfeeding (months)  Parous no breastfeeding220118403611Reference   1--66872577510970.97(0.84, 1.11)   7--126662545212101.16(1.01, 1.34)   13--20546645449221.08(0.93, 1.25)   21--30362030435771.04(0.88, 1.22)   \>30206717363311.10(0.91, 1.33)    *p*-trend0.14 Menopausal status  Premenopausal256820355331Reference  Perimenopausal227918764030.73(0.63, 0.86)  Postmenopausal264372200044160.66(0.59, 0.75)   *p*-trend\<0.0001 Age at menopause (years)  \<47541245958171Reference  47--49515143248271.10(0.99, 1.22)  50--529831821816131.13(1.03, 1.24)  \>526663550811551.15(1.04, 1.28)  Premenopausal256820355331.81(1.57, 2.10)   *p*-trend^b^0.01 Age at start of oral contraceptives (years)  14--18309725775201Reference  19--20335626866701.19(1.02, 1.38)  21--24419034907000.95(0.82, 1.11)  25--50430735907170.91(0.77, 1.07)  Never used145321200024430.95(0.85, 1.07)   *p*-trend^a^0.06 Duration of oral contraceptives (years)  Never used145321200024431Reference  \<2401934056140.89(0.81, 0.99)  2--5375831206381.02(0.92, 1.13)  6--10345328346191.10(0.99, 1.22)  \>10271822035151.11(1.00, 1.25)   *p*-trend0.01 Age at start of intrauterine device (years)  14--28134011202201Reference  29--35142211742481.03(0.84, 1.27)  36--4211939652281.18(0.95, 1.46)  43--5010528591931.06(0.85, 1.33)  Never used217341800036930.99(0.84, 1.16)   *p*-trend^a^0.27 Duration of intrauterine device (years)  Never used217341800036931Reference  \<27296121170.92(0.75, 1.14)  2--59697911781.07(0.90, 1.28)  6--10140311582451.10(0.95, 1.28)  \>10175314323211.14(0.99, 1.30)   *p*-trend0.03 Hormone therapy use  Never156881300024871Reference  Past10548865618921.16(1.08, 1.25)  Estrogen current146812192491.03(0.88, 1.20)  Estrogen and progesterone current9536612922.32(1.97, 2.72)   *p*-trend\<0.0001 Duration of hormone therapy (years)  Never used156881300024871Reference   \< =3363630665701.00(0.90, 1.10)  4--8244920134361.17(1.03, 1.30)  \>8406031519091.58(1.42, 1.70)   *p*-trend\<0.0001 Duration of estrogen and progesterone therapy (years)  Never used156881300024871Reference   \< =5428835527361.13(1.02, 1.25)  \>5418932389511.61(1.46, 1.78)   *p*-trend\<0.0001^a^The category *Never used* was not included in the analysis of *p*-trend. bThe category *Premenopausal* was not included in the analysis of *p*-trend. \**p* for trend and OR mutually adjusted for age (50--54, 55--59, 60--64, 65--70 years at screening), body mass index (BMI) (≤22, 23--25, 26--28, \>28 at screening), education (no education/primary school, high school, bachelor's or master's degree), age at menarche (9--12, 13, 14, 15--18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal)

Number of pregnancies was inversely associated with risk of breast cancer overall and risk of several breast cancer subtypes (Table [2](#Tab2){ref-type="table"}). Compared to women who had never been pregnant, those with ≥4 pregnancies had about 40% or lower risk of developing luminal-like breast cancer, and all three tests for trend were statistically significant (Table [2](#Tab2){ref-type="table"}). There were similar, but non-significant protective associations also with HER2-positive and triple-negative tumors, but neither the point estimate for the top category (≥4 pregnancies: OR = 0.60, 95% CI 0.31--1.19 and OR = 0.70, 95% CI 0.41--1.21, respectively), nor the trend for number of pregnancies was statistically significant. The test for heterogeneity comparing triple-negative cancer to luminal A-like cancer was statistically significant.Table 2Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes associated and reproductive factorsLuminal A-likeLuminal B-like HER2-negativeLuminal B-like HER2-positiveHER2-positiveTriple-negativeER+ PR+ HER2-ER+ PR- HER2-ER+ PR+/PR- HER2+ER- PR- HER2+ER- PR- HER2-Controls (*n*)Cases (*n*)OR\*95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIAge at first birth (years) 13--2039517461Reference10011691Reference553961Reference279541Reference495951Reference 21--2222774601.04(0.91, 1.18)6201201.22(0.93, 1.59)305510.97(0.65, 1.43)170320.97(0.58, 1.62)326651.10(0.77, 1.57) 23--2531525910.97(0.85, 1.10)7591571.29(1.00, 1.67)437921.27(0.90, 1.78)222360.75(0.46, 1.22)393861.27(0.89, 1.81) 26--3024735471.12(0.98, 1.28)6471411.30(0.99, 1.71)343621.21(0.82, 1.78)216410.97(0.59, 1.58)318631.16(0.79, 1.70) 31--509372381.19(0.99, 1.43)223601.60(1.10, 2.32)127321.64(0.98, 2.74)63231.67(0.89, 3.12)120291.47(0.88, 2.47) Never (nulliparous)11993281.76(1.44, 2.15)303891.96(1.31, 2.91)164492.74(1.57, 4.78)84271.82(0.85, 3.88)144341.58(0.89, 2.81)  *p*-trend^a^0.070.010.060.490.16  *p*-heterogeneity^\#^0.190.190.310.68Number of pregnancies lasting 6+ months 011993281Reference303891Reference164491Reference84271Reference144341Reference 115963970.91(0.77, 1.08)426840.68(0.48, 0.96)229420.53(0.33, 0.86)128200.50(0.26, 0.96)224410.70(0.42, 1.16) 2626613020.76(0.66, 0.88)16023230.68(0.52, 0.90)8421850.71(0.49, 1.04)426970.78(0.47, 1.29)8131580.77(0.50, 1.18) 338837210.66(0.57, 0.77)9501970.69(0.52, 0.93)528890.54(0.36, 0.82)319600.61(0.36, 1.03)4771170.98(0.63, 1.53) \>415182370.56(0.46, 0.68)383650.58(0.40, 0.84)225310.42(0.25, 0.70)98190.60(0.31, 1.19)196360.70(0.41, 1.21)  *p*-trend\<0.00010.020.0020.190.88  *p*-heterogeneity0.310.420.340.03Parous women only Duration breastfeeding (months)  No breastfeeding9972041Reference260511Reference146331Reference78101Reference135241Reference  1--631456070.95(0.79, 1.15)8311701.01(0.70, 1.45)449740.66(0.40, 1.07)243371.42(0.63, 3.18)467801.01(0.60, 1.71)  7 − 1231086631.09(0.91, 1.31)7631581.05(0.73, 1.51)427980.83(0.51, 1.33)215522.25(1.02, 4.99)359951.65(0.98, 2.78)  13 − 2025834961.02(0.83, 1.24)6541300.98(0.67, 1.44)343770.90(0.54, 1.49)156482.51(1.11, 5.68)308691.29(0.74, 2.23)  21 − 3017003191.03(0.83, 1.28)399790.97(0.64, 1.46)240370.60(0.33, 1.10)147281.78(0.74, 4.28)222441.18(0.65, 2.15)  \>309661951.15(0.89, 1.48)250481.03(0.63, 1.69)121160.69(0.33, 1.47)70131.82(0.67, 4.97)123241.19(0.58, 2.44)   *p*-trend0.220.900.630.120.52   *p*-heterogeneity0.850.250.560.84 Menopausal status  Premenopausal11713511Reference208471Reference173321Reference100181Reference130291Reference  Perimenopausal10552290.61(0.50, 0.74)225500.95(0.60, 1.51)152260.86(0.47, 1.54)79201.41(0.67, 2.94)143371.13(0.64, 1.99)  Postmenopausal1200024050.51(0.43, 0.60)32316610.84(0.58, 1.23)16633381.11(0.69, 1.78)8761851.21(0.66, 2.23)15813200.82(0.50, 1.33)   *p*-trend\<0.00010.300.460.710.21   *p*-heterogeneity\<0.00010.010.0010.003 Age at menopause (years)  \<4725584501Reference6381361Reference333471Reference203221Reference336611Reference  47--4923934491.09(0.94, 1.26)6371280.98(0.74, 1.29)321601.48(0.96, 2.27)180392.05(1.14, 3.70)291721.50(1.01, 2.24)  50--5245718701.11(0.98, 1.26)11622410.98(0.77, 1.24)6441311.59(1.09, 2.32)324762.21(1.31, 3.75)6111021.04(0.72, 1.49)  \>5230516331.12(0.97, 1.28)8401640.95(0.73, 1.24)415941.70(1.13, 2.55)202482.36(1.33, 4.21)395881.38(0.94, 2.01)  Never (premenopausal)11713512.34(1.93, 2.85)208471.17(0.76, 1.80)173321.50(0.86, 2.61)100181.76(0.81, 3.80)130291.55(0.88, 2.72)   *p*-trend^a^0.120.720.010.0040.38   *p*-heterogeneity0.700.090.080.28^a^The category *Never* was not included in the analysis of *p*-trend. \**p* for trend and OR mutually adjusted for age (50--54, 55--59, 60--64, 65--70 years at screening), body mass index (BMI) (≤22, 23--25, 26--28, \>28 at screening), education (no education/primary school, high school, bachelor or master's degree), age at menarche (9--12, 13, 14, 15--18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal). ^\#^ *p* for heterogeneity across subtypes was determined in a case − case model (see "[Methods](#Sec2){ref-type="sec"}"). *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2

Later age at first birth was associated with an increased risk of breast cancer overall and with several breast cancer subtypes (Table [2](#Tab2){ref-type="table"}). Compared to those with an early first birth (≤20 years), women with a later age at first birth (\>30 years) were at slightly increased risk of luminal A-like (OR = 1.19, 95% CI 0.99--1.43) and luminal B-like HER2-negative breast cancer (OR = 1.60, 95% CI 1.10--2.32, *p*-trend = 0.07 and 0.01, respectively). The ORs associated with the oldest age at first birth (\>30 years) were also similarly elevated, but not significantly so, for HER2-positive (OR = 1.67, 95% CI 0.89--3.12) and triple-negative (OR = 1.47, 95% CI 0.88--2.47) subtypes (*p*-trend = 0.49 and 0.16, respectively). However, the test for heterogeneity comparing each subtype to luminal A-like breast cancer was not statistically significant for age at first birth.

Duration of breastfeeding was not statistically significantly associated with breast cancer overall (*p*-trend = 0.14) (Table [1](#Tab1){ref-type="table"}) or with any of the subtypes (Table [2](#Tab2){ref-type="table"}). Postmenopausal status was associated with a statistically significantly reduced risk of breast cancer overall (Table [1](#Tab1){ref-type="table"}) and of luminal A-like breast cancer compared to being premenopausal (OR = 0.51, 95% CI 0.43--0.60), while no association was observed for any of the other subtypes, and all tests for heterogeneity were statistically significant. Age at menopause, comparing women \>52 to women \<47 years old was positively associated with risk of luminal B-like HER2-positive (OR = 1.70, 95% CI 1.13--2.55, *p*-trend = 0.01) and HER2-positive (OR = 2.36, 95% CI 1.33--4.21, *p*-trend = 0.004) subtypes (Table [2](#Tab2){ref-type="table"}).

Duration of oral contraceptive use and use of an IUD, were associated with a slight increased risk of breast cancer overall (Table [1](#Tab1){ref-type="table"}), with 10% elevated ORs among women with the longest duration of use. The effect estimates for long duration of oral contraceptive use were similar, but not statistically significant, for luminal A-like (OR = 1.11, 95% CI 0.96--1.29) and luminal B-like HER2-negative (OR = 1.12, 95% CI 0.81--1.54) subtypes. Women who had used an IUD for more than 10 years had an increased risk of luminal A-like breast cancer compared to never users (OR = 1.35, 95% CI 1.14--1.61) (Table [3](#Tab3){ref-type="table"}). We observed no evidence of any clear associations for the other subtypes, and in fact a reduced OR for the luminal B-like HER2-positive (OR = 0.51, 95% CI 0.27--0.96) subtype (*p*-heterogeneity with luminal A-like breast cancer = 0.009) (Table [3](#Tab3){ref-type="table"}).Table 3Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes and oral contraceptives and hormone therapyLuminal A-likeLuminal B-like HER2-negativeLuminal B-like HER2-positiveHER2-positiveTriple-negativeER+ PR+ HER2-ER+ PR- HER2-ER+ PR+/PR- HER2+ER- PR- HER2+ER- PR- HER2-Controls (*n*)Cases (*n*)OR\*95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIAge at start of oral contraceptives (years) 14--1814762851Reference334651Reference187451Reference128171Reference180551Reference 19--2014623871.33(1.11, 1.59)367871.20(0.82, 1.75)230490.90(0.55, 1.45)133271.52(0.75, 3.10)206460.67(0.42, 1.07) 21--2419594051.05(0.87, 1.25)458921.04(0.71, 1.53)295450.62(0.37, 1.02)130241.45(0.69, 3.04)253410.44(0.27, 0.74) 25--5019933970.99(0.83, 1.20)5361020.97(0.66, 1.43)296580.80(0.49, 1.32)114272.23(1.06, 4.71)258580.63(0.39, 1.03) Never used671513441.01(0.86, 1.19)17583630.99(0.71, 1.38)8761800.82(0.53, 1.27)5011152.05(1.08, 3.89)8601650.54(0.36, 0.81)  *p*-trend^a^0.090.430.710.020.03  *p*-heterogeneity^\#^0.600.520.070.02Duration of oral contraceptives (years) Never used671513441Reference17583631Reference8761801Reference5011151Reference8601651Reference \<218393640.97(0.85, 1.11)482800.82(0.62, 1.08)275340.64(0.42, 0.97)151180.47(0.27, 0.81)263430.85(0.58, 1.26) 2--517533611.03(0.90, 1.18)435881.01(0.77, 1.33)233480.94(0.64, 1.37)113170.61(0.34, 1.09)228561.32(0.92, 1.89) 6--1015683321.06(0.92, 1.23)388801.03(0.77, 1.37)240561.23(0.85, 1.76)121351.07(0.66, 1.73)203471.20(0.82, 1.76) \>1012662981.11(0.96, 1.29)271621.12(0.81, 1.54)204450.95(0.64, 1.42)82191.02(0.56, 1.86)149381.25(0.82, 1.90)  *p*-trend\*0.130.510.570.910.11  *p*-heterogeneity^\#^0.610.100.0030.56Age at start of intrauterine device (years) 14--286121251Reference152281Reference82141Reference55121Reference88191Reference 29--356811430.97(0.73, 1.28)152391.31(0.75, 2.30)93100.76(0.30, 1.90)4670.74(0.24, 2.25)78251.42(0.70, 2.88) 36--425321471.33(1.00, 1.77)114210.83(0.43, 1.58)89191.34(0.60, 3.01)4370.75(0.26, 2.16)78120.70(0.31, 1.58) 43 − 504561211.16(0.86, 1.56)136250.86(0.46, 1.59)70111.06(0.42, 2.70)3970.94(0.32, 2.78)70140.94(0.42, 2.12) Never used1000020250.93(0.75, 1.15)26005290.94(0.61, 1.45)13682841.36(0.72, 2.56)7291531.10(0.56, 2.16)12792670.94(0.55, 1.61)  *p*-trend^a^0.070.340.100.400.45  *p*-heterogeneity^\#^0.220.120.200.38Duration of intrauterine device (years) Never used1000020251Reference26005291Reference13682841Reference7291531Reference12792671Reference \<2341640.91(0.69, 1.21)83160.86(0.49, 1.52)56131.23(0.62, 2.43)3350.84(0.31, 2.32)3770.90(0.38, 2.13) 2--54321041.17(0.93, 1.48)112210.95(0.58, 1.56)62110.96(0.47, 1.94)3670.81(0.34, 1.91)57211.79(1.01, 3.16) 6--106151401.16(0.95, 1.42)153401.37(0.94, 2.01)89150.86(0.46, 1.59)5380.62(0.27, 1.43)99201.23(0.72, 2.11) \>108202121.35(1.14, 1.61)176310.96(0.63, 1.46)111120.51(0.27, 0.96)63120.73(0.37, 1.47)120200.75(0.44, 1.28)  *p*-trend\<0.00010.520.060.180.98  *p*-heterogeneity^\#^0.080.010.650.22Hormone therapy use Never741113561Reference17623561Reference10101951Reference5731131Reference9911961Reference Past480910861.27(1.15, 1.40)13612760.98(0.81, 1.18)6881421.07(0.81, 1.42)319650.88(0.60, 1.30)5751261.04(0.79, 1.38) Estrogen current6551311.06(0.86, 1.31)162310.81(0.53, 1.23)85191.14(0.65, 1.99)51121.12(0.54, 2.35)93160.79(0.43, 1.46) Estrogen and progesterone current3451842.92(2.36, 3.62)89331.74(1.10, 2.74)48181.67(0.89, 3.14)3260.88(0.33, 2.30)49100.92(0.43, 1.98)  *p*-trend\<0.00010.340.150.770.72  *p*-heterogeneity^\#^0.050.340.030.01Duration of hormone therapy (years) Never741113561Reference17623561Reference10101951Reference5731131Reference9911961Reference  \< =316253061.09(0.94, 1.26)473960.99(0.76, 1.30)237430.90(0.61, 1.34)134200.66(0.38, 1.16)234410.77(0.52, 1.15) 4--811302401.21(1.03, 1.43)289641.06(0.77, 1.46)155351.19(0.76, 1.87)76191.18(0.65, 2.13)119250.99(0.59, 1.67) \>817565551.84(1.61, 2.11)4851121.24(0.95, 1.61)253631.34(0.91, 1.98)108230.93(0.52, 1.65)222471.04(0.69, 1.56)  *p*-trend\<0.00010.150.140.941.00  *p*-heterogeneity^\#^0.0010.480.110.02Duration of estrogen and progesterone therapy (years) Never741113561Reference17623561Reference10101951Reference5731131Reference9911961Reference  \< =519084121.25(1.09, 1.43)5451141.02(0.79, 1.32)276450.79(0.53, 1.17)153300.92(0.56, 1.53)230541.19(0.81, 1.74)  \> 517965611.80(1.58, 2.06)4961161.18(0.90, 1.54)256711.47(1.00, 2.16)105291.04(0.62, 1.74)211521.34(0.89, 2.02)  *p*-trend\<0.00010.310.270.980.13  *p*-heterogeneity^\#^0.0040.190.190.02^a^The category *Never* was not included in the analysis of *p*-trend. \**p* for trend and OR mutually adjusted for age (50--54, 55--59, 60--64, 65--70 years at screening), body mass index (BMI) (≤22, 23--25, 26--28, \>28 at screening), education (no education/primary school, high school, bachelor or master's degree), age at menarche (9--12, 13, 14, 15--18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal). ^\#^ *p* for heterogeneity across subtypes was determined in a case − case model (see "[Methods](#Sec2){ref-type="sec"}"). *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2

Compared to women who had never used EPT, current use of EPT was associated with an increased risk (OR = 2.32, 95% CI 1.97--2.72) of breast cancer overall (Table [1](#Tab1){ref-type="table"}) and an increased risk of luminal A-like breast cancer (OR = 2.92, 95% CI 2.36--3.62) (Table [3](#Tab3){ref-type="table"}). The ORs for both luminal B-like subtypes were about 1.7, but this was only statistically significant for the luminal B-like HER2-negative subtype. There was no increased risk of triple-negative breast cancer with the use of EPT (*p*-heterogeneity = 0.006). Previous studies have suggested that the effect of menopausal hormone therapy may be modified by BMI, with stronger risk estimates in lean than in obese women. We therefore examined the effect of duration of EPT in different BMI strata. For breast cancer overall, the ORs associated with longer duration of EPT was significantly higher in lean (BMI \<25) than in obese (BMI ≥25) women (*p* for interaction = 0.001) (Table [4](#Tab4){ref-type="table"}). We observed similar effect modifications by BMI in luminal A-like and luminal B-like HER2-negative breast cancer. There was no evidence that BMI modified the associations between duration of EPT and risk of any of the other subtypes (Table [4](#Tab4){ref-type="table"}).Table 4Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer overall and subtypes of breast cancer, and the duration of estrogen and progestin therapy (EPT) by body mass index (BMI)OVERALL breast cancerBMI \<25BMI ≥25Controls (*n*)Cases (*n*)OR\*95% CIControls (*n*)Cases (*n*)OR95% CIDuration of EPT (years) Never used615410561Reference688014021Reference  \< =517403161.20(1.00, 1.44)18124201.13(0.97, 1.32) \>516234951.96(1.64, 2.34)16154561.31(1.12, 1.54)  *p*-trend\*\<0.0001\<0.0001  *p* for interaction0.001Luminal A-like breast cancer Duration of EPT (years)  Never used34245501Reference38927891Reference   \< =59591761.36(1.06, 1.74)9872431.22(0.99, 1.50)  \>58962932.29(1.80, 2.91)9062701.38(1.12, 1.71)   *p*-trend\<0.00010.002   *p* for interaction0.001Luminal B-like HER2-negative breast cancer Duration of EPT (years)  Never used8501731Reference8871781Reference   \< =5257571.13(0.74, 1.71)295590.83(0.54, 1.29)  \>5243711.22(0.79, 1.88)256470.83(0.51, 1.35)   *p*-trend0.340.37   *p* for interaction0.03Luminal B-like HER2-positive breast cancer Duration of EPT (years)  Never used450811Reference5441131Reference   \< =5137160.85(0.40, 1.81)144290.82(0.45, 1.49)  \>5127281.56(0.67, 3.60)130431.56(0.87, 2.78)   *p*-trend0.440.24   *p* for interaction0.52HER2-positive breast cancer Duration of EPT (years)  Never used269541Reference296561Reference   \< =580161.14(0.44, 2.95)77141.38(0.62, 3.08)  \>549131.53(0.57, 4.05)57171.28(0.56, 2.93)   *p*-trend0.410.43   *p* for interaction0.89Triple-negative breast cancer Duration of EPT (years)  Never used457941Reference5221011Reference   \< =5123200.96(0.45, 2.04)110341.40(0.79, 2.47)  \>5113251.27(0.56, 2.86)100271.34(0.71, 2.54)   *p*-trend0.630.25   *p* for interaction0.09\**p* for trend and ORs mutually adjusted for age (50--54, 55--59, 60--64, 65--70 years at screening), BMI (≤22, 23--25, 26--28, \>28 at screening), age at menarche (9--12, 13, 14, 15--18), education (no education/primary school, high school, bachelor's or master's degree), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal). *HER2* human epidermal growth factor receptor 2

When we added grade to the luminal A-like and both luminal B-like definitions, the results changed slightly, but were largely the same ([Appendix](#Sec15){ref-type="sec"}). The largest difference was a slightly stronger effect of current EPT on the luminal A-like subtype (OR = 3.03 when grade was included in the definition versus OR = 2.90 when it was not).

Among the patients (cases), 38% (*n* = 1813) were diagnosed within a month of completing the questionnaire. Because these women could have been symptomatic when they completed their questionnaire, we ran a sensitivity analysis excluding these women. However, this did not affect the results (results not shown).

Discussion {#Sec9}
==========

In this population-based study within a national screening program, we had information on 4748 patients with breast cancer, which makes it one of the largest single studies of breast cancer subtypes. The number of previous pregnancies was associated with a decreased risk, and late age at first birth was associated with an increased risk of luminal-like subtypes. Although not statistically significant, number of pregnancies and age at first birth were also associated with HER2-positive and triple-negative breast cancer. There were larger differences between subtypes with the use of exogenous hormones. Duration of oral contraceptive use and IUDs were weakly associated with luminal A-like breast cancer, while current EPT was associated with an almost threefold increased risk of luminal A-like breast cancer, but was not associated with either HER2-positive or triple-negative cancer.

There have been different methods of classifying breast cancer subtypes. In our study we used the classification from the St. Gallen meeting in 2013 \[[@CR46]\] where we included only ER+ PR+ HER2- as luminal A, while ER+ PR- HER2- was classified as one of the luminal B definitions, while the second luminal B subtype was the one that is more commonly referred to as luminal B, i.e. ER+ and/or PR+ HER2+. In contrast, in the systematic review of 38 studies \[[@CR47]\] they used a wider definition of luminal A (ER+ and/or PR+ and HER2-), and only one luminal B subtype (ER+ and/or PR+ HER2+). Some studies have also added on Ki67 to the definition of luminal B \[[@CR40], [@CR48], [@CR49]\], which may give a more precise definition of luminal B, although Ki67 is notoriously difficult to assess \[[@CR55]\]. Although our luminal A results were much in line with previous studies, there were some slight differences between our study and previous studies of luminal B, as discussed below.

In the current study we also examined triple-negative breast cancer (ER- PR- HER2-). Some studies have added additional markers, to better define the subset that is basal-like, by HER1+ and/or cytokeratin 5/6+ \[[@CR9], [@CR39], [@CR40], [@CR49], [@CR56]\]. As discussed subsequently, this may explain some discrepancies between the results of different studies.

Reproductive factors {#Sec10}
--------------------

Our observation of an inverse association between parity and luminal A-like breast cancer is consistent with the vast majority of studies as summarized in the recent systematic review of 38 studies \[[@CR47]\] and the more recent studies that were not included in the review \[[@CR7], [@CR8], [@CR10], [@CR48]--[@CR51]\]. The results for luminal B breast cancer have been less clear, with studies finding a protective or increased effect, or no effect of parity \[[@CR47]--[@CR50]\]. In the current study, parity was associated with a decreased risk of both luminal B-like subtypes. This is consistent with four out of six studies included in the systematic review \[[@CR47]\] and three of the more recent studies \[[@CR48]--[@CR50]\]. Two of these recent studies had information on Ki-67 \[[@CR48], [@CR49]\]. When we added grade to the luminal A-like and luminal B-like subtypes, the parity results remained largely the same. These results suggest that there is a protective effect against luminal B, and the effect seems apparent regardless of the markers used to define the luminal B subtype.

Although not statistically significant, we found that parity was associated with a decreased risk of HER2-positive breast cancer. This is consistent with the findings in the Nurses' Health Study \[[@CR49]\], but inconsistent with a case--control study from the Breast Cancer Family Registry \[[@CR50]\] and a Korean cohort study \[[@CR48]\], which reported that parity was associated with an increased risk of the HER2-positive subtype. One of these latter studies included very few women with HER2-positive breast cancer and both studies included younger women than the current study.

However, although not statistically significant, we found that parity was associated with a decreased risk of triple-negative breast cancer.

This is inconsistent with several other studies in which parity was associated with no risk \[[@CR48]\], or was associated with increased risk of triple-negative breast cancer \[[@CR7], [@CR47], [@CR50]\]. One of the studies was in African American women who are less likely to breastfeed compared to Caucasian women \[[@CR7]\]. Several studies have used CK5/6 and epithelial growth factor receptor (EGFR) in addition to ER, PR and HER2neu to define a basal-like subtype \[[@CR9], [@CR39], [@CR40], [@CR49], [@CR56]\], and this may be one reason for the inconsistency between our study and these other studies. We included 386 women with triple-negative breast cancer in our study, but few of these had never been pregnant (*n* = 34) or had four or more children (*n* = 36). More notably, our study consisted of older women (aged 50--69 years). Although we did not have information on time since the last pregnancy, we can only speculate that few women in our study had had a recent pregnancy, a factor associated with increased risk of triple-negative cancer \[[@CR57]\]. Perhaps this explains why we did not find an increased risk of triple-negative cancer with multi-parity.

We found that age at first birth (26 years or older) was associated with an increased risk of luminal-like breast cancer. This is consistent with a systematic review and \[[@CR47]\] and two recent studies \[[@CR8], [@CR49]\]. However, age at first birth was only statistically significantly associated with luminal A cancer, whereas in the current study age at first birth was significantly associated with luminal A-like and luminal B-like HER2-negative subtypes. One reason for this difference might be that our definition of luminal B-like HER2-negative cancer was rather similar to the definition of the luminal A-like subtype used in the other studies. In the current study, a non-statistically significant positive association was observed between late age at first birth (31 years or older), and both HER2-positive and triple-negative breast cancer. This is consistent with the Nurses' Health Study \[[@CR49]\], and inconsistent with the case-control study from Korea \[[@CR8]\]. In the latter study, the majority of women were premenopausal, whereas the current study included mainly postmenopausal women.

We found no protective effect of breastfeeding on breast cancer occurrence overall or for any subtype. This is inconsistent with the systematic review that reported that breastfeeding is associated with decreased risk of luminal A-like, luminal B-like and triple-negative subtypes \[[@CR47]\].This may be because our study only included women above 50 years of age, and is consistent with the suggestion that the protective effect of breastfeeding is relatively time-limited, and may be seen predominantly in younger women \[[@CR58]--[@CR60]\]. Several of the more recent studies found a significant protective effect against basal-like breast cancer \[[@CR7], [@CR49]--[@CR51]\]. These studies included both triple-negative breast cancer as in our study and basal-like breast cancer with more markers (CK 5/6 and EGFR) \[[@CR49]\].

Oral contraceptives, intrauterine devices, and menopausal hormone therapy use {#Sec11}
-----------------------------------------------------------------------------

For long duration of oral contraceptive use (\>10 years), we observed a slight increase in risk of all the subtypes except for the luminal B-like HER2-positive and HER2-positive subtypes. Our positive association between duration of oral contraceptive use and triple-negative breast cancer is consistent with the systematic review \[[@CR47]\]. However, two of the three studies in the review reported a decreased risk between oral contraceptive use and the luminal A subtype \[[@CR9], [@CR34]\]. These latter studies were smaller and included younger women (20--74 and \<56 years old) than the current study. There are few data on IUD use. Two studies reported that IUDs were not associated with an increased risk of breast cancer \[[@CR61], [@CR62]\], whereas other studies report that IUDs were associated with an increased breast cancer risk \[[@CR63], [@CR64]\]. We observed a significant positive trend for association between duration of IUD use and breast cancer overall and luminal A-like breast cancer. However, the increased risk of luminal A-like breast cancer was only statistically significant in women using IUDs for more than 10 years. This is consistent with two Finnish studies of levonorgestrel-releasing IUDs and breast cancer \[[@CR63], [@CR64]\], which reported that levonorgestrel-releasing IUDs were associated with an increased risk of breast cancer. One hypothesis is that levonorgestrel-releasing IUDs have substantial progestogenic and androgenic effects \[[@CR63], [@CR64]\], which could contribute to this increased risk with IUD use.

We observed a large increased risk of luminal A-like and a moderate increased risk of luminal B-like breast cancer with use of menopausal hormone therapy, albeit only significantly so for the luminal A-like subtype. This is consistent with a systematic review \[[@CR47]\] and the cohort study from the Nurses' Health Study that investigated only one luminal B subtype, and used Ki-67 to differentiate between luminal A-like and luminal B-like subtypes \[[@CR49]\]. There was some evidence that menopausal hormone therapy was associated with a slightly decreased risk of triple-negative breast cancer when we compared current menopausal hormone therapy users to never users. This is consistent with one of the studies in the systematic review, which was a case-control study from Washington state \[[@CR35]\]. The latter study used the same definition of triple-negative breast cancer as the current study. Inconsistent with our result, studies from the Women's Health Initiative \[[@CR65]\] and the Nurses' Health Study \[[@CR40], [@CR49]\] reported an association between menopausal hormone therapy and increased risk of triple-negative breast cancer. In these latter studies, they used more biomarkers (CK 5/6 and EGFR) to define the basal-like subtype and included younger women than the current study. When we looked at the duration of EPT, compared to never users, women who had used EPT for more than 5 years were at an increased risk of HER2-positive and triple-negative breast cancer. This is consistent with the analysis from the Nurses' Health Study \[[@CR49]\].

We hypothesized that EPT would have a stronger effect on thin women than on heavier women, and our results suggested modification of the effect of the duration of EPT when we analyzed leaner women (BMI \<25) and heavier women (BMI \>25) with the luminal-like subtypes of breast cancer. This is consistent with a previous population-based case--control study of women aged 55--72 years \[[@CR66]\].

Mechanisms and suggested subtype differences {#Sec12}
--------------------------------------------

Pregnancies have been reported to ultimately reduce plasma estrogen (estrone, estradiol and estriol) \[[@CR67]\] and follicular-phase progesterone \[[@CR68]\], and increase sex hormone-binding globulin \[[@CR67]\]. Our findings suggest that both parity and combined menopausal hormone therapy may be predominantly associated with luminal-like breast tumors, with the association being strongest for the luminal A-like subtype. The effect of EPT was stronger when we added grade to the definition of luminal A cancer. We observed little effect of breastfeeding overall, and no clear subtype differences. It is possible that the effect of breastfeeding is non-hormonal, and includes changes in immune responses and apoptosis \[[@CR69], [@CR70]\].

Our results, together with those from other large studies, further suggest that the associations between these hormonal-related factors (parity, age at first birth, oral contraceptive use and menopausal hormone therapy use) and risk of the luminal B-like subtypes are similar to the associations between these factors and risk of the luminal A-like subtype. However, although the association with luminal A was the strongest, it is clear that EPT also increases the risk of breast cancer with bad prognosis \[[@CR71]\].

We observed some intriguing associations with HER2-positive breast cancer. The effect of pregnancies and age at first birth were similar for the HER2-positive subtype and luminal cancer. Also, age at menopause was strongly associated with increased risk only of the HER2-positive subtype. Further, we observed a positive trend of association between age at menopause and the luminal B-like HER2-positive subtype. These results might imply that there are hormonal mechanisms involved in the expression of the HER2 protein. On the other hand, exogenous hormone use (EPT) was not associated with this subtype, suggesting that perhaps only some hormonal mechanisms play a role in HER2-positive subtypes. The contrasting results between the luminal-like subtypes and triple-negative breast cancer are also consistent with previous literature. Hormonal factors have a stronger effect on ER+ PR+ tumors, which suggests that the etiology of triple-negative cancer is different from that of the luminal subtypes. Specifically, this suggests that triple-negative tumors may not be as easily prevented hormonally.

In summary, the strongest discrepancy across subtypes was for the use of combined hormone therapy, where the effect was clearly much stronger for luminal A-like than for other cancers. Otherwise, the associations with hormonal risk factors were stronger for luminal A and B-like subtypes than for HER2-positive and triple-negative subtypes. Our results suggest that reproductive factors may to some extent be associated with HER2-positive tumors, but that triple-negative tumors have a different etiology.

Strengths and limitations {#Sec13}
-------------------------

Strengths of this study include its population-based design, the large size, being the largest single study of breast cancer subtypes conducted so far, and the availability of prospectively collected detailed information on many risk factors for breast cancer.

Although the study is the largest to date, there was still limited power for analysis of the rare breast cancer subtypes. Another weakness was the lack of molecular expression data. This may have obscured differences between the subtypes. Another possible weakness was that a subset of women were diagnosed within a month of completing the questionnaire (*n* = 1813), and could have been symptomatic when they completed their questionnaire. However, exclusion of women who were diagnosed within a month of completing the questionnaire did not affect the results (results not shown).

Women who attend screening might be more health-conscious and have a healthier lifestyle than women who do not attend. This could have contributed to obliteration of protective effects of "healthy" habits, such as an effect of breastfeeding overall. At the same time, women who attend screening are more likely to have breast cancer detected. Thus, the picture becomes complicated with these potential biases, and it is not clear how this would explain the results of this paper. The associations between well-established risk factors and overall risk of breast cancer were largely as expected. Furthermore, it is unlikely that any such bias would have differentially affected the results for different subtypes.

Conclusions {#Sec14}
===========

Reproductive factors and menopausal hormone therapy use were more strongly associated with luminal-like breast cancer, but reproductive factors were also associated with HER2-positive and triple-negative breast cancer. The differences between subtypes were greatest for menopausal hormone use. Our results add to the literature showing that there are etiologic differences between luminal breast cancer subtypes and basal-like or triple-negative breast cancer subtypes, but suggest that the differences may be limited.

Appendix {#Sec15}
========

Table 5Adjusted odds ratios (OR) and 95% confidence intervals (CI) for association between breast cancer subtypes and reproductive and hormonal factors with grade included in the luminal-like subtypesCharacteristicsLuminal A-like: ER+ PR+ HER2-, low and medium gradeLuminal B-like, HER2-negative: ER+ PR- HER2-, high gradeLuminal B-like, HER2 positive: ER+ PR+/PR- HER2+, low/medium/high gradeHER2-positive: ER- PR- HER2+Triple-negative: ER- PR- HER2-Controls (*n*)Cases (*n*)OR\*95% CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95%CIControls (*n*)Cases (*n*)OR95% CIControls (*n*)Cases (*n*)OR95% CIAge at first birth (years) 13--2039516091Reference1001421Reference553911Reference279541Reference495951Reference 21--2222773761.06(0.91, 1.23)620321.31(0.77, 2.25)305470.94(0.62, 1.42)170320.90(0.53, 1.53)326651.13(0.78, 1.62) 23--2531524810.99(0.86, 1.14)759321.42(0.80, 2.52)437871.21(0.85, 1.73)222360.72(0.43, 1.20)393861.28(0.89, 1.85) 26--3024734271.12(0.96, 1.30)647250.71(0.38, 1.31)343591.16(0.78, 1.74)216410.94(0.56, 1.55)318631.13(0.76, 1.67) 31--509371961.27(1.03, 1.57)223151.28(0.58, 2.81)127321.53(0.90, 2.60)63231.65(0.86, 3.17)120291.36(0.80, 2.33)  *p*-trend\*0.060.820.120.530.28  *p*-heterogeneity^\#^0.730.240.710.72Number of pregnancies lasting 6+ months 011992451Reference303151Reference164431Reference84271Reference144341Reference 115963250.95(0.78, 1.15)426180.90(0.42, 1.94)229410.58(0.35, 0.96)128200.50(0.26, 0.96)224410.70(0.42, 1.16) 2626610570.80(0.68, 0.94)1602751.03(0.55, 1.94)8421780.78(0.52, 1.16)426970.78(0.47, 1.29)8131580.77(0.50, 1.18) 338835720.67(0.56, 0.79)950420.93(0.47, 1.82)528810.56(0.36, 0.86)319600.61(0.36, 1.03)4771170.98(0.63, 1.53) \>415181990.62(0.50, 0.77)383130.82(0.36, 1.87)225280.43(0.25, 0.73)98190.60(0.31, 1.19)196360.70(0.41, 1.21)  *p*-trend\<0.00010.660.0020.190.88  *p*-heterogeneity0.850.410.310.04Parous women only Duration breastfeeding (months)  No breastfeeding9971651Reference260101Reference146311Reference78101Reference135241Reference  0--631455000.93(0.76, 1.15)831370.95(0.41, 2.18)449710.67(0.40, 1.10)243371.42(0.63, 3.18)467801.01(0.60, 1.71)  7--1231085271.07(0.87, 1.31)763380.94(0.41, 2.19)427910.84(0.51, 1.37)215522.25(1.02, 4.99)359951.65(0.98, 2.78)  13--2025834020.99(0.80, 1.24)654320.91(0.38, 2.18)343750.94(0.56, 1.58)156482.51(1.11, 5.68)308691.29(0.74, 2.23)  21--3017002631.02(0.80, 1.30)399130.46(0.17, 1.21)240370.67(0.36, 1.24)147281.78(0.74, 4.28)222441.18(0.65, 2.15)  \>309661541.11(0.83, 1.47)25090.81(0.26, 2.53)121120.57(0.25, 1.29)70131.82(0.67, 4.97)123241.19(0.58, 2.44)   *p*-trend0.330.170.690.120.52   *p*-heterogeneity0.720.160.600.85 Menopausal status  Premenopausal11712911Reference208101Reference173301Reference100181Reference130291Reference  Perimenopausal10551750.59(0.47, 0.74)225110.91(0.34, 2.42)152250.82(0.44, 1.50)79201.41(0.67, 2.94)143371.13(0.64, 1.99)  Postmenopausal1200019320.50(0.42, 0.60)32311421.06(0.47, 2.39)16633161.05(0.64, 1.72)8761851.21(0.66, 2.23)15813200.82(0.50, 1.33)   *p*-trend\<0.00010.770.590.710.21   *p*-heterogeneity0.020.010.0010.002Age of menopause (years)  \<4725693671Reference640241Reference334441Reference204221Reference336611Reference  47--4924043731.11(0.94, 1.31)639321.21(0.65, 2.27)326551.34(0.85, 2.10)181392.06(1.14, 3.73)292721.47(0.98, 2.20)  50--5246987041.11(0.96, 1.29)1190511.33(0.76, 2.31)6631231.57(1.06, 2.33)338772.32(1.36, 3.94)6231020.99(0.69, 1.44)  \>5232554911.05(0.90, 1.23)871351.29(0.71, 2.34)442901.71(1.12, 2.61)225482.38(1.33, 4.26)420881.37(0.94, 2.01)   *p*-trend0.600.370.010.0040.42   *p*-heterogeneity0.840.030.060.26 Age at start of oral contraceptives (years)  Never used671510701Reference1758781Reference8761661Reference5011151Reference8601651Reference  14--1814762260.94(0.79, 1.12)334120.72(0.34, 1.50)187441.24(0.80, 1.92)128170.49(0.26, 0.93)180551.86(1.23, 2.81)  19--2014623191.33(1.14, 1.55)367231.35(0.76, 2.39)230471.09(0.72, 1.63)133270.74(0.45, 1.23)206461.24(0.83, 1.85)  21--2419593231.02(0.88, 1.18)458231.14(0.65, 2.00)295430.78(0.53, 1.15)130240.71(0.42, 1.18)253410.82(0.55, 1.22)  25--5019933251.01(0.87, 1.16)536180.71(0.40, 1.25)296541.01(0.70, 1.44)114271.09(0.66, 1.79)258581.17(0.82, 1.67)   *p*-trend0.410.630.560.700.91   *p*-heterogeneity0.770.540.080.02 Duration of oral contraceptives (years)  Never used671510701Reference1758781Reference8761661Reference5011151Reference8601651Reference  \<218392940.97(0.84, 1.13)482190.75(0.42, 1.34)275330.67(0.44, 1.03)151180.47(0.27, 0.81)263430.85(0.58, 1.26)  2--5 years17532951.05(0.91, 1.23)435150.73(0.39, 1.38)233460.95(0.64, 1.41)113170.61(0.34, 1.09)228561.32(0.92, 1.89)  5--10 years15682681.06(0.90, 1.24)388201.02(0.56, 1.85)240541.27(0.87, 1.85)121351.07(0.66, 1.73)203471.20(0.82, 1.76)  \>10 years12662321.09(0.92, 1.29)271141.00(0.49, 2.03)204410.95(0.62, 1.44)82191.02(0.56, 1.86)149381.25(0.82, 1.90)   *p*-trend0.220.910.540.910.11   *p*-heterogeneity0.760.140.0030.66 Age at start of intrauterine device (years)  Never users1000016091Reference26001131Reference13682661Reference7291531Reference12792671Reference  14--286121051.12(0.89, 1.41)15251.14(0.40, 3.24)82140.76(0.40, 1.45)55120.91(0.46, 1.80)88191.07(0.62, 1.83)  29--356811130.99(0.79, 1.23)15271.11(0.45, 2.72)93100.62(0.31, 1.24)4670.68(0.27, 1.68)78251.51(0.90, 2.55)  36--425321211.57(1.25, 1.98)11450.61(0.22, 1.72)89180.95(0.54, 1.69)4370.69(0.29, 1.61)78120.75(0.39, 1.44)  43--50456961.32(1.02, 1.69)13650.97(0.33, 2.86)7080.57(0.25, 1.28)3970.85(0.35, 2.09)70141.01(0.53, 1.90)   *p*-trend00.660.130.310.89   *p*-heterogeneity0.790.070.210.40 Duration of intrauterine device (years)  Never used1000016091Reference26001131Reference13682661Reference7291531Reference12792671Reference  \<2341530.96(0.70, 1.32)8320.81(0.16, 4.02)56121.17(0.58, 2.39)3350.84(0.31, 2.32)3770.90(0.38, 2.13)  2--5 years432891.27(0.98, 1.63)11261.79(0.62, 5.18)62100.85(0.41, 1.76)3670.81(0.34, 1.91)57211.79(1.01, 3.16)  5--10 years6151101.19(0.94, 1.49)15340.49(0.16, 1.43)89130.80(0.41, 1.54)5380.62(0.27, 1.43)99201.23(0.72, 2.11)  \>10 years8201731.36(1.12, 1.64)176101.41(0.62, 3.18)111120.53(0.28, 1.02)63120.73(0.37, 1.47)120200.75(0.44, 1.28)   *p*-trend\<0.00010.900.060.180.98   *p*-  heterogeneity0.710.010.580.31 Hormone therapy use  Never741110851Reference1762801Reference10101831Reference5731131Reference9911961Reference  Past48098801.28(1.15, 1.43)1361631.06(0.71, 1.59)6881321.09(0.82, 1.45)319650.88(0.60, 1.30)5751261.04(0.79, 1.38)  Estrogen current6551071.09(0.86, 1.37)16250.77(0.27, 2.15)85191.28(0.73, 2.26)51121.12(0.54, 2.35)93160.79(0.43, 1.46)  Estrogen and progesterone current3451503.03(2.39, 3.83)8930.80(0.21, 3.04)48151.42(0.72, 2.78)3260.88(0.33, 2.30)49100.92(0.43, 1.98)   *p*-trend\<0.00010.800.190.770.72   *p*-heterogeneity0.020.170.040.005 Duration of hormone therapy (years)  Never used741110851Reference1762801Reference10101831Reference5731131Reference9911961Reference   \< =316252461.10(0.93, 1.29)473211.09(0.62, 1.91)237431.01(0.67, 1.51)134200.66(0.38, 1.16)234410.77(0.52, 1.15)  4--811301971.19(0.99, 1.43)289171.27(0.66, 2.45)155311.14(0.71, 1.83)76191.18(0.65, 2.13)119250.99(0.59, 1.67)  \>817564451.85(1.59, 2.15)485231.01(0.56, 1.80)253581.35(0.91, 2.02)108230.93(0.52, 1.65)222471.04(0.69, 1.56)   *p*-trend\<0.00010.750.150.941.00   *p*-heterogeneity0.110.500.040.01 Duration of estrogen and progesterone therapy (years)  Never741110851Reference1762801Reference10101831Reference5731131Reference9911961Reference   \< =519083211.22(1.04, 1.42)545251.08(0.62, 1.87)276440.85(0.57, 1.27)153300.92(0.56, 1.53)230541.19(0.81, 1.74)  \>517964541.82(1.57, 2.10)496160.77(0.39, 1.50)256641.41(0.95, 2.10)105291.04(0.62, 1.74)211521.34(0.89, 2.02)   *p*-trend\<0.00010.650.300.980.13   *p*-heterogeneity0.0020.330.180.02\**p* for trend and OR mutually adjusted for age (50--54, 55--59, 60--64, 65--70 years at screening), body mass index (BMI) (≤22, 23--25, 26--28, \>28 at screening), education (no education/primary school, high school, bachelor's or master's degree), age at menarche (9--12, 13, 14, 15--18 years), number of pregnancies (0, 1, 2, 3, ≥4), menopausal status (premenopausal, perimenopausal, postmenopausal). ^\#^ *p* for heterogeneity across subtypes was determined in a case--case model (see "[Methods](#Sec2){ref-type="sec"}")

BMI

:   body mass index

CI

:   confidence interval

CISH

:   chromogenic in situ hybridization

CRN

:   The Cancer Registry of Norway

EPT

:   estrogen and progesterone therapy

ER

:   estrogen receptor

FISH

:   fluorescence in situ hybridization

HER2

:   human epidermal growth factor receptor 2

IHC

:   immunohistochemical analysis

PR

:   progesterone receptor

SISH

:   silver in situ hybridization

Not applicable.

Funding {#FPar1}
=======

The study was funded by the Norwegian Cancer Society, which had no role in the design, collection of data, analysis or interpretation of the study.

Availability of data and material {#FPar2}
=================================

The data supporting the findings of this study are available at the Cancer Registry of Norway for investigators with the appropriate Norwegian approvals, but restrictions apply. However, data can be made available from the authors upon reasonable request, and with the permission of the Norwegian Regional Committee for Medical and Health Research Ethics.

Authors' contributions {#FPar3}
======================

MED and LV cleaned the data and ran the statistical analyses and MED drafted the manuscript. LV, ST, SH, and IdSS contributed to the design of the study and interpretation of data and helped revised the manuscript. GU conceived the study and supervised the design, statistical analysis, and manuscript preparation. All authors have read and approved the final manuscript.

Competing interests {#FPar4}
===================

The authors declare that they have no competing interests.

Consent for publication {#FPar5}
=======================

Not applicable.

Ethics approval and consent to participate {#FPar6}
==========================================

Participants were informed that submission of a completed questionnaire indicated that they gave their consent to participate in studies of breast cancer. The study was approved by the Regional Committee for Medical and Health Research Ethics in the South-East Health Region of Norway (2014/1167).
